Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study

A. Veronesi, G. Cartel, D. CriveUari, M. D. Magri, M. Delia Valentina, S. Foladore, M. G. Trovo, O. Nascimben, A. Sibau, R. Talamini, S. Monfardini

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

From September 1986 until December 1991, 139 patients with histologically-proven small cell lung cancer, age <75 years, performance status > 40, absence of brain metastases and no previous treatment, were randomised to receive either CEV cyclophosphamide 1000 mg/m2 intravenous (i.v.), epirubicin 70 mg/m2 i.v., vincristine 1.2 mg/m2 i.v., every 3 weeks or PE (cisplatin 20 mg/m2 i.v. and etoposide 75 mg/m2 i.v. for 5 consecutive days, every 3 weeks) for six cycles. After three cycles, responding patients received radiotherapy to the chest (45 Gy/15 sessions) and to the brain (30 Gy/10 sessions-only in patients with limited disease achieving complete remission). 3 patients were ineligible. Patient characteristics included (CEV/PE) total number 66 70, median age 60 61 years, median performance status 80 80, extended disease 33 48 cases (P = 0.04). In evaluable patients, 42 62 (67.7%) responded to CEV while 42 58 (72.4%) responded to PE (P = non-significant); respective complete response rates were 16.1 and 29.3% (P = non-significant) and respective complete response rates in patients with extended disease were 9.4 and 28.9% (P = 0.03). Median survival was 10.5 months, without significant differences in the two treatment arms, even after adjustment for stage. PE was less well tolerated than CEV. Although PE is more active than CEV in certain subsets of patients, its apparent inability to improve survival in this and in other studies questions its routine use in small cell lung cancer.

Original languageEnglish
Pages (from-to)1474-1478
Number of pages5
JournalEuropean Journal of Cancer
Volume30
Issue number10
DOIs
Publication statusPublished - 1994

Fingerprint

Epirubicin
Small Cell Lung Carcinoma
Vincristine
Etoposide
Cyclophosphamide
Cisplatin
Survival
Brain
Arm
Radiotherapy
Thorax
Neoplasm Metastasis
Therapeutics

Keywords

  • chemotherapy
  • small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Veronesi, A., Cartel, G., CriveUari, D., Magri, M. D., Valentina, M. D., Foladore, S., ... Monfardini, S. (1994). Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study. European Journal of Cancer, 30(10), 1474-1478. https://doi.org/10.1016/0959-8049(94)00253-2

Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer : a randomised study. / Veronesi, A.; Cartel, G.; CriveUari, D.; Magri, M. D.; Valentina, M. Delia; Foladore, S.; Trovo, M. G.; Nascimben, O.; Sibau, A.; Talamini, R.; Monfardini, S.

In: European Journal of Cancer, Vol. 30, No. 10, 1994, p. 1474-1478.

Research output: Contribution to journalArticle

Veronesi, A, Cartel, G, CriveUari, D, Magri, MD, Valentina, MD, Foladore, S, Trovo, MG, Nascimben, O, Sibau, A, Talamini, R & Monfardini, S 1994, 'Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study', European Journal of Cancer, vol. 30, no. 10, pp. 1474-1478. https://doi.org/10.1016/0959-8049(94)00253-2
Veronesi, A. ; Cartel, G. ; CriveUari, D. ; Magri, M. D. ; Valentina, M. Delia ; Foladore, S. ; Trovo, M. G. ; Nascimben, O. ; Sibau, A. ; Talamini, R. ; Monfardini, S. / Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer : a randomised study. In: European Journal of Cancer. 1994 ; Vol. 30, No. 10. pp. 1474-1478.
@article{ab8ae9d1f34345acb501adae47fdefbe,
title = "Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study",
abstract = "From September 1986 until December 1991, 139 patients with histologically-proven small cell lung cancer, age <75 years, performance status > 40, absence of brain metastases and no previous treatment, were randomised to receive either CEV cyclophosphamide 1000 mg/m2 intravenous (i.v.), epirubicin 70 mg/m2 i.v., vincristine 1.2 mg/m2 i.v., every 3 weeks or PE (cisplatin 20 mg/m2 i.v. and etoposide 75 mg/m2 i.v. for 5 consecutive days, every 3 weeks) for six cycles. After three cycles, responding patients received radiotherapy to the chest (45 Gy/15 sessions) and to the brain (30 Gy/10 sessions-only in patients with limited disease achieving complete remission). 3 patients were ineligible. Patient characteristics included (CEV/PE) total number 66 70, median age 60 61 years, median performance status 80 80, extended disease 33 48 cases (P = 0.04). In evaluable patients, 42 62 (67.7{\%}) responded to CEV while 42 58 (72.4{\%}) responded to PE (P = non-significant); respective complete response rates were 16.1 and 29.3{\%} (P = non-significant) and respective complete response rates in patients with extended disease were 9.4 and 28.9{\%} (P = 0.03). Median survival was 10.5 months, without significant differences in the two treatment arms, even after adjustment for stage. PE was less well tolerated than CEV. Although PE is more active than CEV in certain subsets of patients, its apparent inability to improve survival in this and in other studies questions its routine use in small cell lung cancer.",
keywords = "chemotherapy, small cell lung cancer",
author = "A. Veronesi and G. Cartel and D. CriveUari and Magri, {M. D.} and Valentina, {M. Delia} and S. Foladore and Trovo, {M. G.} and O. Nascimben and A. Sibau and R. Talamini and S. Monfardini",
year = "1994",
doi = "10.1016/0959-8049(94)00253-2",
language = "English",
volume = "30",
pages = "1474--1478",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer

T2 - a randomised study

AU - Veronesi, A.

AU - Cartel, G.

AU - CriveUari, D.

AU - Magri, M. D.

AU - Valentina, M. Delia

AU - Foladore, S.

AU - Trovo, M. G.

AU - Nascimben, O.

AU - Sibau, A.

AU - Talamini, R.

AU - Monfardini, S.

PY - 1994

Y1 - 1994

N2 - From September 1986 until December 1991, 139 patients with histologically-proven small cell lung cancer, age <75 years, performance status > 40, absence of brain metastases and no previous treatment, were randomised to receive either CEV cyclophosphamide 1000 mg/m2 intravenous (i.v.), epirubicin 70 mg/m2 i.v., vincristine 1.2 mg/m2 i.v., every 3 weeks or PE (cisplatin 20 mg/m2 i.v. and etoposide 75 mg/m2 i.v. for 5 consecutive days, every 3 weeks) for six cycles. After three cycles, responding patients received radiotherapy to the chest (45 Gy/15 sessions) and to the brain (30 Gy/10 sessions-only in patients with limited disease achieving complete remission). 3 patients were ineligible. Patient characteristics included (CEV/PE) total number 66 70, median age 60 61 years, median performance status 80 80, extended disease 33 48 cases (P = 0.04). In evaluable patients, 42 62 (67.7%) responded to CEV while 42 58 (72.4%) responded to PE (P = non-significant); respective complete response rates were 16.1 and 29.3% (P = non-significant) and respective complete response rates in patients with extended disease were 9.4 and 28.9% (P = 0.03). Median survival was 10.5 months, without significant differences in the two treatment arms, even after adjustment for stage. PE was less well tolerated than CEV. Although PE is more active than CEV in certain subsets of patients, its apparent inability to improve survival in this and in other studies questions its routine use in small cell lung cancer.

AB - From September 1986 until December 1991, 139 patients with histologically-proven small cell lung cancer, age <75 years, performance status > 40, absence of brain metastases and no previous treatment, were randomised to receive either CEV cyclophosphamide 1000 mg/m2 intravenous (i.v.), epirubicin 70 mg/m2 i.v., vincristine 1.2 mg/m2 i.v., every 3 weeks or PE (cisplatin 20 mg/m2 i.v. and etoposide 75 mg/m2 i.v. for 5 consecutive days, every 3 weeks) for six cycles. After three cycles, responding patients received radiotherapy to the chest (45 Gy/15 sessions) and to the brain (30 Gy/10 sessions-only in patients with limited disease achieving complete remission). 3 patients were ineligible. Patient characteristics included (CEV/PE) total number 66 70, median age 60 61 years, median performance status 80 80, extended disease 33 48 cases (P = 0.04). In evaluable patients, 42 62 (67.7%) responded to CEV while 42 58 (72.4%) responded to PE (P = non-significant); respective complete response rates were 16.1 and 29.3% (P = non-significant) and respective complete response rates in patients with extended disease were 9.4 and 28.9% (P = 0.03). Median survival was 10.5 months, without significant differences in the two treatment arms, even after adjustment for stage. PE was less well tolerated than CEV. Although PE is more active than CEV in certain subsets of patients, its apparent inability to improve survival in this and in other studies questions its routine use in small cell lung cancer.

KW - chemotherapy

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0027993133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027993133&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(94)00253-2

DO - 10.1016/0959-8049(94)00253-2

M3 - Article

C2 - 7833105

AN - SCOPUS:0027993133

VL - 30

SP - 1474

EP - 1478

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -